You by no means hear “100%” in drugs. The trial was probably the most profitable we’ve ever seen for HIV prevention. The drug was protected, too (it’s already accredited to deal with HIV infections). And it solely wanted to be injected twice a yr to supply full safety.
This week, the outcomes of a small section I trial for as soon as-yearly lenacapavir injections had been introduced at a convention in San Francisco. These early “first in human” trials are designed to check the security of a drug in wholesome volunteers. Nonetheless, the outcomes are extremely promising: All of the volunteers nonetheless had the drug of their blood plasma a yr after their injections, and at ranges that earlier research counsel will defend them from HIV infections.
I don’t usually get too enthusiastic about section I trials, which normally contain only a handful of volunteers and sometimes don’t inform us a lot about whether or not a drug is more likely to work. However this trial appears to be completely different. Collectively, the lenacapavir trials might deliver us a major step nearer to ending the HIV epidemic.
First, a fast recap. We’ve had efficient pre-exposure prophylactic (PrEP) medicine for HIV since 2012, however these have to be taken both each day or simply earlier than an individual is uncovered to the virus. In 2021, the US Meals and Drug Administration accredited the primary long-acting injectable drug for HIV prevention. That drug, cabotegravir, must be injected each two months.
However researchers have been engaged on medicine that provide even longer-lasting safety. It may be troublesome for individuals to recollect to take each day drugs once they’re sick, not to mention once they’re wholesome. And these medicines have a stigma hooked up to them. “Individuals are involved about individuals listening to the drugs shake of their purse on the bus … or seeing them on a drugs cupboard or bedside desk,” says Moupali Das, vp of HIV prevention and virology, pediatrics, and HIV scientific improvement at Gilead Sciences.
